- Adjusted EPS grew 56% driven by higher adjusted EBITDA, favorable foreign exchange, and lower interest expense.
- Adjusted gross margin improved 470 basis points to 45.6%, with Affordable Medicines segment margin up 270 basis points to 44.3%.
- Affordable Medicines revenue was $433 million, growing 1% despite last year's 14% growth, driven by new product launches adding $33 million.
- AvKARE revenues declined 4% to $163 million but improved gross margin by 540 basis points and operating income by 44%.
- First half 2025 revenues grew 4%, adjusted EBITDA grew 12% to $354 million, and adjusted EPS increased 50% to $0.45.
- Net leverage reduced to 3.7x adjusted EBITDA from 3.9x in December 2024 following a successful debt refinancing that extended maturities to 2032 and reduced interest costs by over $33 million annually.
- Q2 revenues reached $720 million with adjusted EBITDA of $184 million, reflecting 3% revenue growth and 13% adjusted EBITDA growth year-over-year.
- Specialty segment revenue grew 23% to $128 million, led by CREXONT ($11 million), RYTARY ($9 million, up 19%), and UNITHROID ($4 million, up 12%).
Related items and other data are not available for this feed item.
Dafinchi